GSK plc announced on February 12, 2024, that it received US FDA Fast Track designation for bepirovirsen to treat chronic hepatitis B, addressing a significant unmet medical need affecting nearly 300 million people worldwide.
AI Assistant
GSK PLC
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.